Details of the Drug

General Information of Drug (ID: DMLIAA7)

Drug Name

NX-13

Synonyms

Amelenodor; Amelenodor [INN]; NX-13 free base; DVH35H3HDB; 2389235-01-0; NX-13; UNII-DVH35H3HDB; 1,3,5-Tris((6-methylpyridin-2-yl)oxy)benzene; 2,2',2''-(1,3,5-Benzenetriyltris(oxy))tris(6-methylpyridine; 2,2',2''-(Benzene-1,3,5-triyltris(oxy))tris(6-methylpyridine); Pyridine, 2,2',2''-(1,3,5-benzenetriyltris(oxy))tris(6-methyl-; 2,2',2''-[1,3,5-Benzenetriyltris(oxy)]tris[6-methylpyridine; 2,2',2''-[benzene-1,3,5-triyltris(oxy)]tris(6-methylpyridine); Pyridine, 2,2',2''-[1,3,5-benzenetriyltris(oxy)]tris[6-methyl-; CHEMBL5095087; SCHEMBL22061849; AKOS040756180

Indication

Disease Entry	ICD 11	Status	REF
Ulcerative colitis	DD71	Phase 2	[1]
------------------------------------------------------------------------------------

Drug Type

Small molecule

Structure

3D MOL

2D MOL

Chemical Identifiers

Formula: C24H21N3O3
Canonical SMILES: CC1=NC(=CC=C1)OC2=CC(=CC(=C2)OC3=CC=CC(=N3)C)OC4=CC=CC(=N4)C
InChI: InChI=1S/C24H21N3O3/c1-16-7-4-10-22(25-16)28-19-13-20(29-23-11-5-8-17(2)26-23)15-21(14-19)30-24-12-6-9-18(3)27-24/h4-15H,1-3H3
InChIKey: OPUQKVNCXCWRLR-UHFFFAOYSA-N

Cross-matching ID

PubChem CID: 146651362
TTD ID: D4W2AC

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
NLR family member X1 (NLRX1)	TTKT026	NLRX1_HUMAN	Agonist	[2]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

MIA Detail

Jump to Detail Molecular Interaction Atlas of This Drug

References

1	ClinicalTrials.gov (NCT05785715) A Randomized, Double-Blind, Placebo-Controlled, Multiple Dose, Multicenter Phase 2 Induction Study With Long-Term Extension to Evaluate the Clinical Activity and Safety of Oral NX-13 in Participants w/ Moderate to Severe Ulcerative Colitis. U.S.National Institutes of Health.
2	Exploratory studies with NX-13: oral toxicity and pharmacokinetics in rodents of an orally active, gut-restricted first-in-class therapeutic for IBD that targets NLRX1. Drug Chem Toxicol. 2022 Jan;45(1):209-214.